CURRENT SIGNAL - BUY on 11/15/13
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other novel drug technologies in the Americas, Europe, and Asia. It develops prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, as well as for other therapeutic applications. The company, through its commercial partner, Takeda Pharmaceutical Co., Ltd., offers AMITIZA in the United States for the treatment of chronic idiopathic constipation in adults; opioid induced constipation in adults with chronic non-cancer pain; and irritable bowel syndrome with constipation in adult women. It also provides AMITIZA in Japan through its commercial partner, Abbott Japan Co., Ltd., for chronic constipation in adults; and in the United Kingdom and Switzerland for the treatment of chronic idiopathic constipation. In addition, Sucampo Pharmaceuticals markets RESCULA in the United States for the treatment of open-angle glaucoma and ocular hypertension. The companys pipeline also includes AMITIZA, which will begin a Phase III trial for pediatric functional constipation. Its other pipeline products consist of cobiprostone, which is in Phase I clinical development for the treatment of oral mucositis; SPI-017, which is in Phase II clinical development for the treatment of spinal stenosis; and SPI-3608, which is in Phase I clinical development for the treatment of spinal stenosis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.
Market Trend Signal
Stock Analysis Software and Trading System